Last reviewed · How we verify
Hydronidone (Placebo Group)
Hydronidone is a placebo control agent with no active pharmacological mechanism.
At a glance
| Generic name | Hydronidone (Placebo Group) |
|---|---|
| Sponsor | Beijing Continent Pharmaceutical Co, Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo group assignment in a clinical trial, Hydronidone contains no active pharmaceutical ingredient and produces no direct therapeutic effect. It serves as a control comparator to assess the efficacy and safety of an active investigational drug by isolating the true pharmacological benefit from placebo response.
Approved indications
Common side effects
Key clinical trials
- A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B. (PHASE3)
- QTc Assessment in a Single-Dose Study of Hydronidone Capsules (PHASE1)
- The Phase Ⅰd Clinical Trial of Hydronidone Capsules (PHASE1)
- Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis (PHASE3)
- Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. (PHASE3)
- A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydronidone (Placebo Group) CI brief — competitive landscape report
- Hydronidone (Placebo Group) updates RSS · CI watch RSS
- Beijing Continent Pharmaceutical Co, Ltd. portfolio CI